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Cancer is a life-threatening illness and innovative research is therefore required to fuel 
the development of new anti-cancer therapies. As an anti-proliferative drug, hydroxyurea 
(HU) has been used in the treatment of various neoplastic and non-neoplastic diseases 
such as sickle cell anemia, psoriasis, and viral infections. HU is a well-known inhibitor of 
ribonucleotide reductase (RNR), an enzyme that generates dNTPs for DNA replication 
and repair. In our genetic screen in fission yeast looking for mutants with defects in 
checkpoint response, we also found a set of mutants that are highly sensitive to HU but 
with a functional checkpoint response. It is likely that in addition to the RNR 
suppression, HU induces cell lethality by a previously less understood mechanism 
involving perturbations of various metabolic pathways. This study is to identify new 
metabolic genes whose mutations sensitize the cells to HU in order to better understand 
the cell-killing mechanisms of HU. We have identified new mutation in erg12 gene, 
which encodes the mevalonate kinase enzyme in the ergosterol biosynthesis pathways. 
While characterizing the erg12 mutant, we have unexpectedly found five multi-copy 
suppressors including mns1, uge1, chs1, mug109 and hba1. Results from this study may 
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help to better understand the cell-killing mechanisms of HU, the side effects, and drug 
resistance associated with the HU-based chemotherapies. They may also promote 
therapeutic innovations for the benefits of patients with cancer or fungal infections. 
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The DNA replication checkpoint 
There are two DNA structural checkpoint signaling pathways operating in the fission 
yeast Schizosaccharomyces pombe. The first is the DNA replication checkpoint (DRC) 
which is activated in the presence of arrested replication forks during S-phase [4,26]. The 
other is the DNA damage checkpoint (DDC) which is activated during G1 or G2 phase 
when DNA is damaged [4,26]. The DRC is a surveillance signaling pathway activated to 
prevent the genomic instability in response to replication stress. Under stressful 
conditions, errors may happen while replicating DNA, which affects the genome integrity 
and causes mutations. The activated DRC also protects the perturbed forks against 
collapse. Several factors could perturb the DNA replication such as nucleotide depletion, 
damage on the DNA templates, and polymerase inhibitors [4,10,27]. Activated DRC 
stimulating the cellular signaling to promote cell survival and prevent mutations. In our 
lab, HU has been used as an agent that activates the DRC and we look for mutants in 
fission yeast with a dysfunctional DRC. Since the DRC is highly conserved in all 
eukaryotes, the new checkpoint mechanism discovered in fission yeast is likely conserved 
in higher eukaryotes including humans. During the screening of these dysfunctional DRC 
mutants (chk mutants), we unexpectedly screened a group of non-checkpoint mutants 
because the cell lethality is not caused by replication stress induced by HU. 
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The checkpoint signaling pathways 
The DRC signaling pathway is started by the sensor kinase Rad3 (ATR ataxia 
telangiectasia homolog) with its regulatory subunit Rad26 (human ATRIP). Rad3 begins 
the DRC signaling followed by recruitment of other downstream proteins to the stalled 
replication forks. Rad3-Rad26 complex interacts with RPA-coated single-stranded DNA 
(ssDNA) generated at the perturbed forks. Another complex called 9-1-1 (Rad9-Rad1-
Hus1) is also loaded onto the perturbed forks with the help of Rad17 and the replication 
factor C complex RFC2-4, followed by transducer proteins and effectors (Figure 1) 
[4,10,26]. These checkpoint proteins assembled at the perturbed forks to properly amplify 
the checkpoint signal, targeting various downstream proteins responsible for stimulating 
the cellular responses under replication stress. Although these activation mechanisms of 
the checkpoint kinases have been well characterized in mammalian and yeast cells, how 
they exactly become activated under replication stress remains controversial. Cells 
lacking a functional DRC treated by HU, the DDC pathway is activated, suggesting the 
unprotected forks collapse leading to broken forks that activates the DDC to suppress cell 
division and stimulate DNA repair [26,27,34]. Studies in mammalian cell lines observed 
the resistance to HU treatment by up-regulating RNR small subunit (Suc22 in yeast). In 
yeast, the up regulation of Suc22 also suppresses the HU sensitivity of wild type and 




Figure 1: The DRC signal transduction pathway. 
When the forks are perturbed during the S phase, the sensor kinase Rad3/Rad26 (ATR/ATRIP in 
mammalian cells) initiates the signaling cascade by interacting with RPA protein attached to the 
ssDNA. The 9-1-1 complex consisting of Rad1, Rad9 and Hus1 is also loaded with the help of a 
clamp holder Rad17 and Rfc2-4. Rad3 is then activated by the mediator proteins Mrc1 (Claspin in 
human cells) which induces the downstream phosphorylation of the effector kinase protein of the 
DRC, Cds1 (CHK2 in human cells). In the presence of collapsed or broken forks, Rad3 activated 
by the other mediator Crb2 (TP53BP1 in human cells) which facilitates the phosphorylation of 
Chk1, the effector kinase for the DDC. HU treatment arrests DNA replication in proliferating 




The Checkpoint (chk) and the metabolic (non-chk) mutants 
Methyl methane sulfonate (MMS) is one of the DNA alkylating agents, a major class of 
anti-cancer drugs. MMS alters the bases in the DNA template by methylation which 
blocks the polymerase movement during DNA replication [27]. Therefore, it is used in 
this study to differentiate between the checkpoint (chk) and the metabolic (non-chk) 
mutants.  The chk mutants have mutations in genes involved in the DRC signaling 
pathway and they are highly sensitive to the replication stress induced by hydroxyurea 
(HU) as well as the DNA damaging agents such as MMS and UV [26,27,34]. 
Furthermore, HU arrests the chk mutants in S-phase and the chk mutants can be 
suppressed by overexpressing Suc22, the small subunit of RNR and the primary target of 
HU. On the other hand, the non-chk mutants have mutations in metabolic genes. These 
mutants are highly sensitive to chronic HU treatment but are resistant to MMS and UV. 
In addition, they cannot be rescued by Suc22 overexpression as the cell lethality is not 
caused by replication stress but by the less-understood cell-killing mechanisms of HU. 
Consistent with the new cell-killing mechanisms, HU arrests the non-chk mutants in 
G2/M, not the S-phase of the cell cycle [26,27,34]. Examples of these metabolic mutants 
that have been identified previously in our lab are erg11, hem13, ccr1, hcs1, mvd1, erg7, 





The therapeutic effects of HU and its primary cellular target RNR  
HU has been used as an antimetabolite drug as well as for the management of sickle cell 
anemia (SCA). The chemical structure of this agent is shown in Figure 2. HU attracts the 
scientific interest due to its multiple clinical applications. The mechanism for HU’s 
therapeutic effect cannot exactly be explained, but it is generally believed to be as an 
inhibitor of ribonucleotide diphosphate reductase (RNR) (Figure 3) which is absolutely 
needed in converting the ribonucleoside diphosphates to deoxyribonucleoside 
diphosphates (dNDP) [7,17,26]. Indeed, HU treatment arrests the proliferating cells in S 
phase. The small subunit of RNR containing a metal center, producing a tyrosyl free 
radical. HU decreases the cellular dNTP levels by specifically quenching the tyrosyl free 
radical and thus slow the replication forks [7,27]. In response to the slowed fork, the 
DRC becomes activated to stimulate the RNR enzyme, increasing the dNTP production 
to promote fork progress and preventing the forks against collapsing. In addition, the 
activated DRC delays mitosis so the cell can properly finish the DNA replication after the 
HU effect is removed [7,26,27]. Since the cell-killing mechanism of HU remains poorly 
understood, studies suggested that HU might have an unknown secondary target inside 
cells besides the RNR. Identification of such targets may improve the HU-based 



















              Figure 3: Structure of ribonucleotide reductase 
Ribonucleotide reductase enzyme (RNR) consists a larger subunit R1 and a smaller subunit R2 
(Suc22 in fission yeast ) required for the synthesis of deoxyribonucleotides (dNTPs) by 
catalyzing the reduction of NDPs. The activated DRC inhibits cell devision by upregulates RNR 
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to promote the dNTP production. Therefore, the HU sensitivity of the DRC mutants has been 
reported to be suppressed by overexpression of Suc22 [26,27]. 
 
Secondary target(s) of HU 
Recent studies suggested that in addition to RNR, HU may induce cell lethality by 
targeting other cellular targets. Although the DRC defects in chk mutants sensitize the 
cell to HU, hus mutants have been identified that carry a functional DRC. The cell death 
in these non-chk mutants was due to cytokinesis arrest or oxidative stress in the presence 
of mutations in heme or sterol biosynthesis pathways [26,27]. Screening for such mutants 
provides an insight to the novel cell-killing mechanisms of HU. These hus mutants are 
therefore classified as metabolic mutants or ‘non-chk’ mutants. In our lab, seven non-chk 
mutations of various metabolic pathways have been identified previously, including 
erg11, erg7, erg25 in ergosterol biosynthesis pathway, mvd1 and hcs1 in mevalonate 
pathway, and hem13 and ccr1 in heme biosynthesis pathway [26,27]. The mechanisms 
behind the cytotoxic effect of HU in these non-chk mutants are due to cytokinesis arrest, 
oxidative stress or other uncharacterized mechanisms but not due to the RNR inhibition, 
which induces S-phase arrest and DRC activation [26,27,34]. Screening and 
characterization more metabolic mutants may thus help to identify the secondary cellular 
target of HU and to better understand the cell-killing mechanisms of this clinically 
important drug. Here, I report our identification and characterization of a metabolic 




The cytokinesis arrest in HU-treated erg11-1 mutant  
Previous screening for new HU sensitive mutants in our lab has identified a novel 
mutation in erg11 involved in ergosterol biosynthesis [26,34]. The gene product of erg11 
is the enzyme sterol-14a-demethylase (Cyp51in humans), which is highly conserved in 
all eukaryotes (Figure 4). Interestingly, Erg11 is known to be the major therapeutic target 
of antifungal agents used in the clinics such as clotrimazole and terbinafine. Further 
analysis has been done in this mutant in order to understand the mechanism by which this 
mutation induces HU sensitivity. It has been noticed that HU at low doses stably arrests 
erg11-1 mutant cells in cytokinesis, which is the cytoplasmic division of the cell before 
separating into two daughter cells. erg-11 mutant cells appear to have a sterol deficiency 
as determined by fluorescent microscopy. The mutant enzyme may also produce a toxic 
byproduct, leading to HU sensitivity. To investigate this possibility, exogenous ergosterol 
was added to the erg11-1 mutant to test whether the mutant can be rescued chemically. 
However, the results showed that the erg11-1 could not be rescued by exogenous 
ergosterol as the cell lacks the transporter that prevents the use exogenous sterol. Another 
test was to examine the effect of Erg11 inhibitors clotrimazole and terbinafine on the 
erg11-1 mutant. While the checkpoint mutants, including rad3, cds1, and chk1 showed a 
similar resistance as in wild type cells, the erg11-1 cells were much more sensitive to the 
inhibitors. All together, these results showed that the sterol deficiency is likely the reason 
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for the observed cytokinesis arrest and HU sensitivity [26,34]. Furthermore, various drug 
combinations of HU with the Erg11 inhibitors (antifungal azoles) have synergistic cell-
killing effects on fission yeast as well as the fungal pathogen C. albican [26,34]. Beside 
the erg11-1 mutation, mutations in erg7 and erg25 in the ergosterol pathway have also 
been found in our lab although not further characterized yet. 
 
The oxidative stress induced by HU in hem13-1 mutant  
In our lab, another novel mutation T263D in hem13 gene has also been identified. This 
gene is predicted to encode coproporphyrinogen III oxidase enzyme in heme biosynthesis 
that is homologous to coproporphyrinogen oxidase (CPOX in humans) [27]. HU 
treatment in this mutant generates a significant oxidative stress. Consistent with this 
mechanism, flow cytometry analysis of the hem13-1 mutant cells showed that HU 
arrested the cells at G2/M phase, not the S phase. Thus, the HU-induced cell death in this 
mutant is by the accumulated ROS inside the cells. Further experimental evidence is that 
treatment with the antioxidant N-acetylcysteine (NAC) promotes cell survival in HU and 
exogenous hemin completely rescues the mutant. Interestingly, pretreatment of wild type 
cells with sampangine, the inhibitor of hem13 significantly enhanced the cell-killing 




 Use of the fission yeast Schizosaccharomyces pombe as a model organism 
The fission yeast S. pombe is a rod-shaped unicellular eukaryote that contains only three 
chromosomes [11]. It divides by medial fission and grows by tip elongation. Most of the 
cellular processes are conserved in S. pombe, making it an excellent laboratory organism 
for studying the cellular and molecular mechanisms that are conserved in higher 
eukaryotes, including humans. S. pombe also offers several technical advantages in this 
study: it has a rapid life cycle between 2 to 4 hours at 36 ̊C–25 C̊. It is easy to handle and 
to isolate mutants for studying a particular process of interest in either haploid or diploid 
cells [11].  The specific metabolic pathways that have been studied for this thesis using 
this model are described below. 
 
Ergosterol biosynthetic pathway 
Ergosterol (cholesterol in mammalian cell membranes) is an integral component of the 
fungal cell membrane. It is vital for cell growth and development since it is involved in 
the coordination of many other pathways that maintain the fluidity, stability and integrity 
of the cell [1,2,3]. Due to its importance, the ergosterol biosynthesis pathway has been 
studied intensely as a target of antifungal drugs like "azole" class [6,23,25]. It is also 
considered as vitamin D2 precursor and used in steroid hormone drugs. The perturbations 
of ergosterol synthesis could cause deficiency of sterol which alters the membrane 
functions as well as mitochondrial activities [25]. The biosynthesis of ergosterol (Figure 
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4) is a complex process and involves enzymes that can be separated in three major parts: 
mevalonate, farnesyl pyrophosphate (farnesyl-PP) and ergosterol biosynthesis [3,13]. 
Mevalonate pathway is started by the synthesis of HMG-CoA by the enzyme ERG13. 
Following the synthesis of HMG-CoA, farnesyl pyrophosphate (farnesyl-PP) is 
synthesized by the enzymes ERG12, ERG8, ERG19, IDI and ERG20, which are essential 
enzymes for cell growth. The last part mainly occurs in the endoplasmic reticulum (ER), 
done by 15 steps, converting the farnesyl-PP to squalene follow by the biosynthesis of 
lanosterol and then ergosterol. Inhibiting the HMG-CoA reductase in the mevalonate 
pathway by statins affects the production of all intermediate molecules that are needed 
for ergosterol as well as for other biosynthetic pathways like ubiquinone, dolichol, and 
isoprenoids (Figure 4), which likely lead to various side-effects associated with statins 
[3,13]. Therefore, developing a drug targeting specifically the downstream enzymes of 







Figure 4: Ergosterol biosynthetic pathway. 
Different parts of the ergosterol biosynthetic pathway are shown including the names of the 




Somanon Bhattacharya et al. mBio 2018; doi:10.1128/mBio.01291-18 
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Multi copy suppressors 
Overexpression of a suppressor gene can make the cell able to bypass a gene mutation 
leading to rescuing the mutant phenotype. The suppression interactions tend to happen in 
genes that have a related functional pathway. Therefore, screening for the suppressors has 
been used extensively to identify genes that are involved in the related pathways, which 
may guide to the discovery of new therapeutic opportunities [27]. In this study, five genes 
have been found whose upregulation can suppress the mutations in ergosterol pathway. 
Three of them are genes involved in cell wall formation including mns1, uge1, and chs1. 
The other two suppressors are classified as Ras superfamily genes (see below). 
 
Ras superfamily  
The Ras superfamily is a group of small GTP-binding proteins that are categorized in six 
subfamilies (Fig 5A) [19].  Ras superfamily proteins are involved in many cellular 
functions associated with the regulation of cell growth and cell survival like signal 
transduction pathways and mevalonate pathway [19,24]. A previous study has shown that 
a mutation in Ras protein are associated with the up to 30% of all human cancers [19]. 
Ras proteins can undergo by farnesylation or geranylgeranylation (Fig 5B) which 
controls several cellular processes involving in the cell proliferation and vesicle 
trafficking. Furthermore, many members of the Ras protein superfamily are 
polyprenylated leading to hydrophobic modifications which further control the cell 
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membrane. Hence, they are linked to the prenylation correlated diseases [8,19,24]. 
Combination therapy of prenylation inhibitors with the standard therapy may enhance the 
treatment of some incurable and devastating diseases. They are considered as an 
intermediate component in the mevalonate pathway [19]. During the screening of the 
mutations that sensitizes the cell to HU, two of the Ras family genes, mug109 encoding 
Rab GTPase binding protein and hba1 encoding Ran GTPase binding protein have been 
identified. Upregulation of these two particular genes may therefore improve the survival 
in HU of a mutant cells with defect in sterol biosynthesis. 
  
                        
   A B 
                                                           W. Likus et al. / Drug Resistance Updates 25 (2016) 13–25 
Figure 5: Ras superfamily 
A. The 6 subfamilies of Ras-superfamily. B. The mevalonate pathway with a series of 
intermediate steps leading to various products. The synthesis of farnesylpyrophosphate (FPP) 
pathway is further divided into a number of branches including the biosynthesis of cholesterol, 
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ubiquinone, heme A and dolichols. Ras proteins can be either farnesylated or geranylgeranylated 
by the protein prenylation process [19]. 
 
Yeast cell wall 
The fungi’s cell wall is the most significant structural difference from mammalian cells. 
The integrity of fungal cell wall depends on cell wall polysaccharides. Some of these 
polysaccharides are present only in fungi and are therefore considered as excellent targets 
for antifungal chemotherapies. The main components of the fungal cell wall 
polysaccharides are 𝛽-1,3 glucan, 𝛽-1,6 glucan, and various glycoproteins/ 
mannoproteins (Fig.6), which are essential for the maintenance of intracellular osmotic 
pressure and for the integrity of the cell wall [1,14,18]. The chemical structure and the 
biosynthesis of the fungal cell wall components have been studied extensively due to 
their significant roles in various pathways like the regulation of MAPK signaling 
pathways [1,14,18]. The MAPK signaling pathways are activated when the cell wall is 
damaged to activate the repair processes of the cell wall. During the screening of the 
mutation that sensitizes the fission yeast to HU, I have found the cell wall enzymes 
including Mannosyl-oligosaccharide 1,2  𝛼 -mannosidase (mns1), UDP-glucose 4-
epimerase (uge1), and Chitin Synthase (chs1). These particular enzymes may therefore 
function in the regulation of the ergosterol biosynthesis pathway for maintaining the cell 




Figure 6: Yeast cell wall structure 
First, β-1,3-glucan is synthesized from UDP-glucose (UDP-Glc) by β-1,3-glucan synthase, then 
β-1,6-glucan is added to the β-1,3-glucan followed by addition of mannoprotein to make 
polysaccharide mannoprotein complex. Finally, chitin is synthesized from UDP-N-
acetylglucosamine (UDP-GlcNAc) by chitin synthase and connected to β-1,6-glucan. The lighter-
colored circles are undefined polysaccharide chains [5]. 
 
Mannosyl-oligosaccharide 1,2-alpha-mannosidase (Mns1) 
Mns1 is involved in glycoprotein catabolic process, particularly in the protein 
glycosylation pathway [5,14,30]. It is located in the membrane of endoplasmic reticulum 
membrane and Golgi, removing one mannose residue from the glycosylated protein 
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which is essential for early N-glycan processing. Therefore, α-mannosidase is considered 
as ER-associated protein degradation (ERAD); responsible for trimming 
Man9GlcNAc2 N-glycans in the endoplasmic reticulum to form Man8GlcNAc2 isomer B 
which is the substrate for oligosaccharide elongation [5,14,30]. It is believed that the 
degradation role of ER mannosidase is independent on its enzymatic activity. The human 
homologue of Mns1 is MAN1B1whose mutations are associated with mental retardation 
diseases. A previous study has shown that disruption of the mns1 gene cause defects in 
the degradation of certain misfolded glycoproteins [30]. Selective inhibitor of α-
mannosidase enzyme could block the abnormal oligosaccharides formation, leading to 
reduction of metastasis and tumor growth [16,30]. Kifunensine is a well-known α-
mannosidase enzyme Inhibitor. Targeting this enzyme may also help in designing novel 
therapeutic agents that prevent the degradation of misfolded proteins in some genetic 
diseases that are characterized by rapid degradation of misfolded glycoproteins [30]. 
 
UDP-glucose 4-epimerase (Uge1) 
S. pombe glycoproteins contain a large amount of galactose and mannose. Uge1 is the 
key enzyme involved in the galactose synthesis (Leloir pathway) (Figure 7) in cytosol 
[28,32]. It converts β-D-galactose to glucose-1-phosphate and the predominant enzyme 
involved in galactosylation of glycoproteins in S. pombe. The human homologue of Uge1 
is called GALE whose mutations are associated with galactosemia [28,32]. A previous 
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study has shown that uge1 deletion strain exhibits a severe defect in galactosylation [6]. 
A deletion library screens study has been done for screening the sensitivity of antifungal 
drugs showed that uge1 deletion sensitizes the yeast cells to Micafungin, an antifungal 




Figure 7: Leloir pathway of galactose metabolism 
Galactose is phosphorylated by galactokinase to form galactose-1-phosphate, which is then 
transformed to glucose-1-P by uridylyltransferase. UDP-galactose can also be formed from UDP-
glucose via the UDP galactose-4’-epimerase Uge1 (GALE in humans) reaction. 
 
Chitin synthase (Chs1)   
Chs1 has the glycosyltransferase activity, an enzyme that is responsible for converting 
the UDP-N-acetylglucosamin (UDP-GlcNAc) to chitin [18,21]. Chitin, which is 
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composed of 𝛽-(1,4) N-acetyl-D-glucosamine (GlcNAc), will then be connected to 𝛽-
1,3-glucan and 𝛽-1,6-glucan for building larger polysaccharide complexes in the cell wall 
synthesis. The major function of Chs1 is for the formation of primary septum during 
cytokinesis as well as a vital role in cell separation after cytokinesis. The synthesis of the 
spore cell wall in S. pombe requires Chs1 and previous studies have shown that the ∆chs1 
strain forms abnormal asci [21,33,15]. Different from human cells, chitin is considered as 
a unique fungi’s cell wall polysaccharide. The uniqueness of this enzyme makes it an 















1. Genetic screening to identify the mutated genes in the non-chk mutant M9 that is 
sensitive to HU. 
2. Identification of the mutation in M9. 







HU inhibits RNR, which slows down the DNA replication process and activates the DRC 
to upregulate RNR and promote DNA synthesis. However, dysfunctional DRC is not the 
only way that lead to the cell death in the presence of HU.  Recent studies have shown 
that HU induces cytokinesis arrest or oxidative stress in non-chk mutants of various 
metabolic pathways [25,26,27]. 
In this study, we have used genetic methods in the fission yeast S. pombe to screen for a 
metabolic mutation that sensitizes the cells to HU. The identified mutation in the 
ergosterol pathway and its multiple copy suppressors gene screened during this study 





MATERIALS AND METHODS 
Yeast strains, plasmids and chemical compounds 
All yeast strains were grown in YE6S media (0.5% yeast extract, 3% glucose, and the 6 
supplements of adenine, uracil, histidine, lysine, leucine, and arginine) or in the EMM6S 
media (lacking one of the appropriate supplements) at 30˚C. The mutagen methyl 
nitrosoguanidine (MNNG) was used to generate random mutations in the genome of a 
wild type S. pombe strain. HU was purchased from Sigma and dissolved in distilled water 
as a 1.0 M stock solution. Phloxin B dye was used as an indicator of cell lethality. All 
yeast strains used in this study are listed in Table 1, whereas the PCR primers and the 
plasmids are listed in Table 2 and Table 3, respectively. The plasmids and mutations were 
confirmed by DNA sequencing (Retrogen, San Diego, CA).  
Drug sensitivity test 
The drug sensitivity of the screened mutants was measured by the spot assay. The strains 
grown overnight in an appropriate medium. 1 OD/ml cells (1 OD = 2x107 yeast cells of 
logarithmically growing fission yeast culture) was diluted in 3-fold or 6-fold steps.  Three 
μl of the serial dilution cells was spotted onto YE6S plates as a control plate or YE6S 
plates containing different concentration of HU (2.5 mM or 5 mM). Wild type cells were 
used as negative control while the HU-sensitive Δrad3 cells as positive controls. The 
plates were incubated at 30˚C for 2-3 days and then photographed. 
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The collection of metabolic (non- chk) mutants. 
A collection of the metabolic mutants by genetic screening that are sensitive to HU but 
resistant to the DNA damaging agent MMS was provided by Rittu Samuel, a former MS 
graduate student in our lab. This genetic screening was started by crossing the new set of 
the metabolic mutants with the known mutants in our lab (erg11, ccr1, and hcs1) to 
eliminate known mutations. These mutants were then backcrossed with the parental 
strains three times to remove the by-stander mutations followed by intercrossing 
(crossing these mutants with each other) to identify the complementation groups, in 
which two mutants of opposite mating type were spotted on top of each other to 
determine if they are allelic or not. The HU resistant spots suggest that the two mutants 
have mutations in different genes and are non-allelic. Sensitive spots indicate that the 
mutants being crossed likely have mutations in the same genes or allelic. Finally, nine 
complementation groups were identified by Rittu Samuel, suggesting nine potential 
metabolic genes involved. Currently, three of these potential metabolic genes has been 
identified (erg7, erg25 previously and erg 12 in this study). Therefore, five more 
unknown metabolic genes remain to be identified.  
• Group 1: M7, U1, YX347, YX406, YX433 
• Group 2: M9, M12 
• Group 3: U5, SN79, YX35, YX86, YX102, YX147, YX482, YX503 
• Group 4: M38, YX175 
• Group 5: YX71, YX171, YX397, YX517 
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• Group 6: YX146, YX210 
• Group 7: YX348, YX499 
• Group 8: SN31 
• Group 9: YX180 
 
Identification of the mutated gene(s) in M9 mutant  
M9 mutant from group 2 was selected randomly for transformation with a genomic 
library marked with ura4 by electroporation. The colonies grown on EMM plates lacking 
uracil were tested the HU sensitivity. The HU resistant colonies were selected to recover 
the plasmids that confer HU resistance to M9. The recovered plasmid DNAs were 
digested with the restriction enzymes EcoRI, EcoRV and HindIII followed by analysis in 
agarose gel electrophoresis. The bands obtained were compared with that of the empty 
vector and then classified into different subgroups. From each subgroup, a representative 
plasmid was selected to be transformed back into the M9 mutant to confirm the conferred 
HU resistance. The plasmids that showed HU resistance partially or completely after 
retransformation were then sequenced to identify the genes that confer M9 with HU 





Identification of the mutations in erg12 
The genomic DNA from the M9 mutant was purified. Based on the sequences of the 
identified genes, cloning primers were designed that amplified a 2988 bp PCR product of 
erg12. The conditions used for Phusion PCR amplification was 98ºC denaturation 
temperature, 50ºC annealing temperature and 72ºC as extension temperature for 1 
minutes and 30 seconds (30 cycles) using a Thermal Cycler. The PCR product was 
analyzed by agarose electrophoresis. Band was cut out for purification of the PCR 
product. The purified PCR product was sequenced using the primers specifically 
designed for sequencing erg12 in order to identify the mutations in this particular gene.  
 
Screening for multiple-copy suppressors of erg12 mutant 
The erg12 mutant was transformed with genomic DNA libraries that carry the ura4 
marker. The transformed mutant cells were plated on media lacking uracil followed by 
replica plating on HU plates to screen for HU resistance colonies. The recovered 
plasmids for the HU-resistant yeast colonies were sent out for DNA sequencing and 
identification of the suppressor genes. The suppressor genes showing in sequence results 
have been cloned and retransform to the erg12 mutant strain and retest the HU 
sensitivity. The yeast transformation was performed using the lithium acetate method. 
Cells were grown up overnight then harvested by centrifugation. Pellets were washed 
with sterile water 3 times then resuspend in 100 mM lithium acetate (pH 4.9). 1l of 
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plasmid DNAs were added to 100 µl cells and then mixed with 290 l of 50% PEG3350 
in 100 mM lithium acetate (pH 4.9). The cells were incubated for 1 h at room temperature 
and then heat-shocked for 30 min at 42 ˚C. After recovering in the rich YE6S media at 













Table 1: List of S. pombe strains used in the study 
Strain Genotype Source 
TK7 h- leu1-32 ura4-D18 ade6-M210  Xu Lab 
TK48 h+ leu1-32 ade6-M210  Xu Lab 
NR1826 h- ∆rad3::ura4 leu1-32 ura4-D18 ade6-M210 P. Russell Lab 
YJ1298 h+ erg11(G189D):kanR leu1-32 ura4-D18 ade-M216 Xu Lab 




Table 2: List of PCR and sequencing primers used in the study 
Name Sequence (5’ -> 3’) Note 
SpErg12(T)SphI-f atacgCAtgcagtaacgttgtcc Gene Cloning 
SpErg12(P)SacI-b tgcaGAGctccttcaaaaaggagc Gene Cloning 
SpErg12(450-469)f TTGGCAGCATGTAACAGTGG Sequencing 
SpErg12(886-905)f CATCAGAGTGCCATGAAAGA Sequencing 
SpErg12(561-580)b GGGTACAAAGCATTGCTGAG Sequencing 
SpMns1(P)PstI-f aggtCTgcagccttattcttctacc Gene Cloning 
SpMns1(T)BamHI-b gtccggAtcctaatacaataaatcaag Gene Cloning 
SpMns1(529-507)b CATTTGATCTAGGTAAGCCCGTG Sequencing 
SpMns1(409-432)f GGAGGACTCCTTTCTTCTTATCAC Sequencing 
SpMns1(1031-1052)f CTTCATTAGAAGCAGCACGTAC Sequencing 
SpUge1(P)SphI-f tcggGCatgcttgtttaccagcagg  Gene Cloning 
SpUge1(T)XmaI-b atgtCCCgggtattaagtgtagtttg  Gene Cloning 
SpUge1(639-618)b CCATACACGGTAGCAGATGAAG Sequencing 
SpUge1(441-460)f CAGCTTTGGACAAGGTCTTC Sequencing 
SpUge1(822-842)f   GTGAACTCGGTGAAGATCCTC Sequencing 
spChs1(P)SphI-f aataGCAtgcggtgatatttaaaatgag Gene Cloning 
spChs1(T)SacI-b cttaGagctccatatacaacggcatg Gene Cloning 
SpChs1(454-75)f  GAGCGAGAATTTGCTTACATGC Sequencing 
SpChs1(540-20)r GGGCTGCCTTAAAGTGAATAG Sequencing 
SpChs1(1017-36)f  TTTAGATGCTGGAACACGTC Sequencing 
SpChs1(1545-66)f TGCTATCTGTCACTACTACAGG Sequencing 
SpChs1(2137-56)f  TGCAACACACATGACGTTTC Sequencing 
SpMug109(P)PstI-f    5’ttacCTGcagccctaaaagcgtatac Gene Cloning 
SpMug109(T)SacI-b    5’aaatGAGctcaatcctgaacttctgg Gene Cloning 
SpMug109(356-339) b      ACACCAGGGATGGAATAC Sequencing 
SpMug109(237-256) f   CCCATTTGCTTTGTTAGCTC Sequencing 
SpHba1(P)SphI-f   5’ttgtGCAtgcgctcgagctatcgattag    Gene Cloning 
SpHba1(T)SacI-b     5’taagGAGctcttgaataaaattatatttg      Gene Cloning 
SpHba1(586-605) b  TCTGTTTCAACTGCTGTTCC     Sequencing 
SpHba1(431-454) f CTTCATTCTCTAATGCCTCGTCTC Sequencing 
SpHba1(832-851)f ATATTCAGTGTTCGCGCAAG Sequencing 









Table 3: List of plasmids used in the study 
Name  Description Source 
pAPS42 Prom+Erg12+term(ura4+) Xu Lab 
pAPS43 Prom+Erg12+term(ura4+)Hus169 Xu Lab 
















Identification of new metabolic mutants 
In order to identify new DNA replication checkpoint (DRC) mutants, we have carried out 
an extensive genetic hus (HU sensitive) screening in the fission yeast S. pombe looking 
for mutants that are sensitive to HU. This screen unexpectedly screened a new group of 
metabolic mutants whose cell death is not caused by the replication stress induced by 
HU, but by the less understood mechanisms involving metabolic mutations, oxidative 
stress and cytokinesis arrest. These hus mutants were classified as non-chk mutants 
because unlike the chk mutants, the non-chk mutants are not sensitive to the DNA 
damaging agent MMS. To reconfirm their non-chk or metabolic mutations, Suc22, the 
RNR small subunit and the major regulation target of the DRC, was overexpressed in 
these mutants. The results showed that these non-chk mutants were not rescued, 
consistent with their mutations in metabolic pathways, not the DRC pathway. The non-
chk M9 mutant that belongs the complementation group 2 was selected randomly for this 
study. To identify the mutation(s) in M9, S. pombe genomic expression libraries made 
from the wild type strain TK7 were transformed into the mutant (Figure 8). The 
expression vector used in this library was pIRT-2U, which has ura4 gene as a selective 
marker. After the transformation by electroporation, the mutant cells were spread onto 
EMM6S medium plates lacking uracil. The yeast colonies formed on the plate were 
replicated onto YE6S plates containing 5 mM HU to screen for HU-resistant colonies. 
After collecting a total of ~30 HU resistant colonies, their HU resistance was examined 
by spot assay analysis (Figure 9). Once the HU resistance was confirmed, the plasmids 
were recovered from the yeast colonies. These recovered plasmids were amplified and 
then purified from E. coli followed by digestion with restriction enzymes EcoRI, EcoRV 
and HindIII (Figure 10). After agarose gel electrophoresis of the digested plasmids, the 
pattern of the bands of each recovered plasmid were examined and compared with those 
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obtained from the empty vector pIRT-2U digested with the same restriction enzymes. As 
a result, 16 different sub-groups of the recovered plasmids (Figure 10) were determined 
for this mutant. A representative of each group of recovered plasmids was then 
retransformed back into the M9 mutant.  The HU sensitivity of the transformed mutants 
was assessed again by spot assay using the mutant itself and wild type cells as the 
controls (Figure 11). 10 plasmids rescued the M9 mutant and therefore the HU resistance 
conferred by those plasmids were reconfirmed by a more accurate 6 spot assay (Figure 
12). These plasmids were then sequenced using primers on both sides of the gene cloning 
site of pIRT-2U in order to identify the genes that are cloned in the vectors and 
responsible for conferring the HU resistance in M9. 
 
Identification of the mutated gene in M9. 
PomBase is the database containing all genomic DNA sequence information of S. pombe. 
It was used as the reference to locate the genes on a particular fragment that is cloned in 
pIRT-2U in the genomic DNA expression library. The sequences obtained from the 
sequencing from either the 5’ or 3’ end using the primers pIRT-f and ura4-prom-b2. For 
the plasmids that rescues M9, alignment of the genomic DNA carried in plasmid #9 or P9 
showed that it contains the expression cassettes of three genes. One is erg12 gene 
encoding the mevalonate kinase enzyme of the ergosterol biosynthetic pathway. The 
second is chs1 encoding the chitin synthase, and the third is aps1 gene that encodes 
diadenosine 5',5'''-p1, p6-hexaphosphate hydrolase. This result suggests that erg12, chs1 
and aps1 are the candidate genes whose mutations may sensitize the M9 cells to HU 
(Figure 13A). Sequence alignment of the DNA fragment from P8 showed that it 
contained two candidate genes that might be mutated in M9, uge1 gene encode UDP-
glucose 4-epimerase and hba1 whose gene product is Ran GTPase binding protein, one of 
the Ras superfamily proteins (Figure 13B). Sequence alignment of the DNA from P16 
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showed that it contained two candidate genes: mns1 encodes mannosyl-oligosaccharide 
1,2-alpha-mannosidase and mug109 encoding Rab GTPase binding protein one of the Ras 





























Figure  8: Flow chart for identification of the mutated genes in the newly screened 
metabolic or non-chk mutants that are sensitive to HU. 
After mutagenizing the wild type S. pombe cells, the HU sensitive mutants were selected. The 
DNA damaging agetnt MMS was used to distinguish between the chk and non-chk mutants. The 
non-chk mutants were classified into 9 complementation groups.  A representative mutant from 
each group was transformed with S. pombe genomic DNA expression libraries derived from the 
wild type strain TK7. The transformed cells were grown up on plates lacking uracil to screen the 
yeast colonies that became resistant to HU. Plasmids recovered from the yeast colonies were 
transfected into ultra-competent DH5α bacterial cells and purified. These plasmids were digested 
using restriction enzymes followed by agarose gel electrophoresis. Plasmids carrying different 
digested pieces of DNA were categorized into sub-groups and a representative from each sub-
group was retransformed into the mutant to confirm the HU resistance by the standard spot assay. 
Plasmids capable to rescue the mutants or suppress the HU sensitivity of the mutants were 




Figure 9: Spot Assay analysis of the HU sensitivity of the isolated M9 colonies after 
the transformation with S. pombe genomic DNA library.  
M9 mutant was transformed with genomic DNA library and the colonies with conferred 
HU resistance were isolated. HU sensitivity of the isolated colonies was assessed by spot 
assay analysis. Wild type and rad3 cells were used as the controls. A total of 30 colonies 
were tested that are partially or fully rescued. Plasmids from the HU-resistant colonies 





Figure 10 : Restriction digestions of the recovered plasmids by EcoRI, EcoRV and 
HindIII. 
The digested plasmids were analyzed by an agarose gel electrophoresis. The band patterns 
obtained were used to categorize the plasmids into sub-groups. 16 sup-groups are listed on the 
right. The stars indicate that plasmids having the bands similar to those obtained from the vector 












Figure 11: Spot assay analysis of the M9 HU resistance colonies after 
retransformation. 
16 recovered plasmids were transformed back into M9 mutant and HU sensitivity of the 
transformed mutant carrying the indicated plasmids was assessed by spot assay. Wild 
type and rad3 cells were used as the controls. All plasmids were sent for DNA 
sequencing except plasmid 1, 4 and 14 that did not show any rescuing effect in M9. 
Plasmid 5, 11, and 12 did not show good sequencing results. Therefore, only 10 plasmids 
















Figure 12 : Spot assay analysis of the M9 resistance colonies after retransformation. 
Spot assay analysis for the 10 plasmids with their corresponding genes responsible for 
rescuing the M9 mutant. Plasmid 8, 9 and 16 were selected for further analysis. The 
names of the genes and their encoded proteins or enzymes are listed below: 
Msm1: mitochondrial methionine-tRNA ligase, Cdc1: DNA polymerase delta small 
subunit, Pfl7: cell surface glycoprotein flocculin, Cox13: cytochrome c oxidase 13, 
SPAC1B2.06: uncharacterized protein, SPAC17G6.03: extracellular 5'-nucleotidase 
human NT5E family, Uge1: UDP-glucose 4-epimerase, Hba1: Ras superfamily, Ran 
GTPase binding protein, Stm1: vacuolar amino acid transmembrane transporter, Csk1: 
cyclin-dependent kinase activating kinase, Mns1: mannosyl-oligosaccharide 1,2-alpha-
mannosidase, Mug109: Ras superfamily, Rab GTPase binding protein, Erg12: 
mevalonate kinase, Chs1: chitin synthase, and Aps1: diadenosine 5',5'''-p1,p6-







B  C 
Figure 13: Identification of the genes that may render mutant M9 resistant to HU. 
A)  Plasmid 9 that rescued the M9 mutant carried three candidate genes erg12, chs1and aps1. 
B) Plasmid 8 that rescued the M9 mutant carried two candidate genes uge1 and hba1. 




Identification of a missense mutation in erg12 gene  
The sequencing and cloning primers were specifically designed for erg12 genes (Table 
2). The genomic DNA was purified from the M9 mutants. The erg12 genes (2988 bp) 
were amplified by PCR using the cloning primers and the high fidelity Phusion DNA 
polymerase. The PCR product (Figure 14A) was analyzed by agarose electrophoreses, the 
band was cut out for purification. The purified PCR product was sequenced using the 
primers specifically designed for sequencing erg12 to identify the potential mutations in 
this particular gene. Based on the sequences result of erg12, a single G-to-A mutation 
that changed the alanine to threonine at amino acid position 142 (A142T). The sequence 
reading done by using the MacVector and 4-Peak software (Figure 14B,14C). The 
mutated amino acid is highly conserved from yeast to humans as shown in Figure 15 
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Figure 14: Identification of a missense mutation in erg12 that likely sensitizes M9 to 
HU. 
A) The PCR product of erg12 gene using SphI and SacI primers. 
B) DNA sequencing of the erg12 PCR product identified a single G-to-A mutation that 
causes A142T amino acid change in the enzyme using 4-Peak software  
C) DNA sequencing of the erg12 identified a single G-to-A mutation that causes A142T 
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Figure 15: The mutated amino acid residues in Erg12 is highly conserved in yeasts, 
mouse and humans. 
Regional amino acid sequences of Erg12 of S. pombe, S. cerevisiae, human, and mouse were 
aligned together. The amino acids highlighted in blue box are the mutated Alanine (A) residues at 
A142T (A148T in human). 
 
Cloning of the erg12 gene  
To confirm that M12 mutant is allelic to M9 or having a mutation also in erg12, erg12 
was cloned (Figure 16) into an S. pombe expression vector. The plasmid was then 
transformed to M9 as well as the M12 mutant. After transformation, the plates were 











Figure 16 : Cloning of erg12 gene  
Wild type and mutant erg12 gene were cloned on pIRT-2U expression vector by PCR with 
primers containing the SphI and SacI sites. The resulting 2988 bp PCR products was purified by 
agarose gel electrophoresis. The purified fragment and the expression vector were digested with 
SphI and SacI enzymes and ligated into the pIRT-2U vector between the SphI and SacI sites. The 
ligation mixture was transformed into 5DH𝛼 competent cells to make copies of recombinant 
DNA plasmids. The transformed cells were spread on plates containing carbenicillin for 24h at 
37℃ . The colonies resistant to the antibiotic were selected for colony PCR screening. The 
plasmids were purified from the positive colonies and then digested with SphI and SacI to 
visualize the bands of vector band and the erg12 expression cassettes that was cloned between 












Figure 17: HU sensitivity of M9 and M12 transformed with vector expressing wild 
type or mutant erg12 as determined by spot assay. 
Expression of wild type and mutant erg12 from the vector fully rescued M9 and M12, which 
shows that consistent with the complementation assay, both M9 and M12 mutants may have the 










Identification of the suppressor genes that may affect the mevalonate pathway  
While identifying the mutations in M9, a few other plasmids also rescued the mutant M9, 
suggesting those plasmids may carry suppressor genes. Plasmid 8 and plasmid 16 were 
selected for further study. As described above, plasmid 8 contained two genes. uge1 gene 
encodes UDP-glucose 4-epimerase and hba1 which is Ran GTPase binding protein 
(Figure 13B). uge1 and hba1 genes were cloned using the method similar to that in erg12 
cloning (Figure18). Plasmid16 contained two genes. The first is mns1 encoding 
mannosyl-oligosaccharide 1,2-alpha-mannosidase and the second, mug109 encoding Rab 
GTPase binding protein (Figure 13C). The cloning of mns1 and mug109 is shown in 
Figure 19. Chitin synthase chs1 gene found in plasmid 9 (Figure 13A) was also cloned to 
study its potential suppressor effect (Figure 20). In total, five candidate genes were 
cloned for testing their suppressor functions. They were transformed into the mutant M9 
then tested the HU sensitivity by spot assay (Figure 21). The results showed that while 
overexpression of mns1, uge1, and mug109 can partially or fully rescuing erg12-1 
mutant. I then transformed these plasmids into other ergosterol mutants screened in our 






















Figure 18: Cloning of uge1 and hba1 genes into the expression vector pIRT-2U.   
A) PCR cloning of uge1 gene into pIRT-2U expression vector between SphI and XmaI sites. 





















Figure 19: Cloning of mns1 and mug109 gene into the pIRT-2U expression vector. 
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A) PCR cloning of mns1 gene into pIRT-2U expression vector between PstI and BamHI sites. 









Figure 20 : Cloning of the chs1 gene.   







Figure 21: Identification of multicopy suppressors of erg12-1 mutant. 
Expression of Mns1, Uge1, Mug109 and Hba1 can partially or fully suppress the HU sensitivity 
of the erg12-1 (M9) mutant. In contrary, expression of Chs1 under similar conditions did not 
rescue the M9 mutant. The wild-type and rad3∆ checkpoint mutant cells were used as a control. 
Vec, empty vector. Three serial dilutions of the cultures of the indicated transformants were 
spotted on YE6S plates or YE6S plates containing 2.5- or 5-mM HU. The plates were incubated 
for 3 days at 30°C and then photographed. 
 
            
 
Figure 22: The multi-copy suppressors of erg7-1 and erg25-1 
Expression of Mns1, Uge1, and Chs1 can suppress the HU sensitivity of the ergosterol mutants 
M38 and M7. Each gene was expressed on erg7-1 (M7) mutant (the left) and on erg25-1 (M38) 
mutant (the right). The wild-type and rad3Δ checkpoint mutant were used as a control. Six serial 
dilutions of the mentioned genes transformation were spotted on YE6S plates and YE6S plates 











Figure 23: Overexpression of mug109 rescued M7, M9 and M38 mutants with 
defects in the ergosterol biosynthesis. 
mug109 was expressed on a vector in erg12-1 (M9) mutant, erg7-1 (M7) mutant, and erg25-1 
(M38) mutant. The wild-type and rad3Δ checkpoint mutant were used as a control. Vec: empty 
vector. Three serial dilutions of the mug109 transformed cells were spotted on YE6S plates or 













In this study, we show that a single missense mutation in erg12 gene that replaces 
residue Alanine142 with threonine in mevalonate kinase (MVK in human), an essential 
enzyme required for mevalonate and ergosterol biosynthesis in all eukaryotes (Figures 4 
and 14). The erg12 mutation significantly sensitizes S. pombe to chronic treatment of 
HU. The mutated alanine residue is highly conserved in all examined eukaryotic enzymes 
(Figure 15), suggesting that it is an important residue for catalysis or protein structure of 
the enzyme. However, the exact mechanism of the HU-mediated cytotoxicity remains 
unknown. Since our previously identified erg11-1 mutant is killed by HU via cytokinesis 
arrest, it is possible that the HU-induced lethality of this erg12 mutant is caused by 
cytokinesis arrest, not DNA replication arrest. The mutation in mevalonate kinase may 
lead to sterol deficiency as in erg11-1 that might be the reason of cytokinesis arrest by 
HU [25,26,34].  
Mevalonate kinase converts mevalonate (mevalonic acid) to mevalonate 
phosphate in the mevalonate pathway. Although this enzymatic step in the mevalonate 
pathway is not rate-limiting, it is controlled by the feedback inhibition by 
geranylpyrophosphate, farnesylpyrophosphate (FPP), and geranylgeranylpyrophosphate 
(GGPP) (Figure 4) [19]. The mevalonate pathway provides the precursor of various 
important biochemical products like prenylated proteins, heme A, dolichol, ubiquinone-
10, isopentenyl tRNAs and cholesterols (Figure 5B) [9,29,12,31]. Inhibition of 
mevalonate kinase may reduce the production of these end products and thereby affect 
diverse cellular processes. Mutations in erg12 may reduce the enzymatic activity of 
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mevalonate kinase and thus sensitizes the cells to the stress induced by HU. In humans, 
mutations in MVK gene cause accumulation of mevalonic acid in body tissues and fluids 
leading to mevalonic aciduria (MVA). Another mild form of mevalonic aciduria is hyper-
immunoglobulinemia D and periodic fever syndrome (HIDS) which is characterize by 
high levels of immunoglobulin D (IgD). The level of mevalonic acid in HIDS patients is 
much lower than in classic mevalonic aciduria and occurs only during episodes of fever 
[9,12]. HIDS and MVA are rare autosomal recessive inherited disorders due to the 
mutations in MVK causing deficiency in MVK enzyme [9,12,31]. Not all MVK mutations 
have the same effect on the enzyme and not all metabolites are affected equally, which 
leads to a broad spectrum of clinical forms of mevalonic aciduria. Literature reported that 
the mutation at A148T in MVK (A142T in Erg12) is responsible for HIDS phenotype 
[12]. The alanine residue resides in the ATP binding site of the enzyme.  Threonine 
substitution of this alanine likely affects ATP binding and thus kinase activity [12]. More 
studies are needed to investigate the effect of this mutation on the activities of other 
metabolite kinases or on ATP binding activity.  
MVA is a fatal multi-systemic disease. Its clinical manifestations begin in infancy 
or in early age, that include psychomotor retardation, failure to thrive, 
hepatosplenomegaly, anemia, progressive cerebellar ataxia, dysmorphic features, 
progressive visual impairment (cataract) and recurrent febrile episodes [12,31]. HIDS is 
milder than MVA condition, only febrile attacks are present concomitant with 
lymphadenopathy, arthralgia, gastrointestinal problems and skin rash. It is not fully 
understood how the inflammatory periodic fever syndrome is related to the reduced 
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activity of MVK. However, the increases of IgD levels are possibly stimulating the 
immune system leading to inflammatory periodic fever syndrome [12,31]. 
As mentioned above, deficient activity of the MVK enzyme affecting the 
production of the isoprenoids leading to shortage of FPP and GGPP and hence reduced 
protein prenylation.  Reduced protein prenylation may cause cluttered overactivation of 
the small GTPases (Ras superfamily), which activate the production of the pro-
inflammatory cytokines like IL-1β, IL-6, IL-18 and TNF (tumor necrosis factor) [12,31]. 
The protein prenylation process influences the functions of many proteins and regulate 
the protein- protein binding with the help of the small GTPases (the Ras super family) 
[8,31]. Disruption of protein prenylation leads to dysfunctional proteins [8,17,19]. 
Interestingly, in this study, two of these Ras family genes were found while studying the 
HU mutant: mug109 encoding Rab GTPase binding protein and hba1 encoding Ran 
GTPase binding protein (Figures 13B,13C). These Ras family genes are identified as 
multiple-copy suppressors of erg12 since they are not mutated in the mutant and their 
overexpression rescue the erg12 mutant (Figure 21). The identified genetic interactions 
among the protein prenylation, Ras family genes, mevalonate pathway and the ergosterol 
pathway may provide explanations for drug resistance or new therapeutic opportunities 
for antifungal or anticancer therapies. For example, previous studies have shown that 
applying the prenylation inhibitors in inhaler with the standard therapy of non-small cell 
lung cancer may improve the therapeutic outcome [19]. Furthermore, prenylation 
inhibitors have antiviral activity and could help in hepatitis cases [8]. 
So far, there is no FDA-approved treatment for MVK deficiency (MKD) or HIDS 
yet [9,12]. But the inflammation and the other symptoms can be reduced to a certain 
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extent. Patients use paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) 
during febrile inflammatory attacks, or moving to corticosteroids (prednisolone), 
proceeding to cytokine blockade like IL-1 receptor antagonist (Anakinra). If failure 
occurs, then use anti-TNF agents. In most severely affected patients, stem cell 
transplantation must be done [9,12]. The results from this study may promote the 
therapeutic innovations for the benefits of patients with HIDS.  
The FPP is also considered as a precursor for the biosynthesis of the dolichol 
chains, which is a cofactor in protein glycosylation, a process initiated in the endoplasmic 
reticulum (ER) and called dolichol-dependent glycosylation that ends with the formation 
of DolPP-oligosaccharide [1,31]. 𝛼1,2-mannosidase enzyme (Mns1) (MAN1B1 in 
human) is an enzyme responsible for protein deglycosylation involved in glycoprotein 
catabolic process and in the cell wall oligosaccharides formation [1]. The 𝛼-glucosidases 
and 𝛼-mannosidases are responsible for trimming the glycoprotein Glc3Man9GlcNAc2 
by removing three glucose and one mannose residues to form smaller oligosaccharide 
Man8GlcNAc2 for further processing and maturation [14,30]. These glycosylation 
reactions are well conserved in the higher eukaryotic organisms. The mns1 gene was 
found in our screening as a multiple-copy suppressor for erg12 mutation. The plasmids 
that contained mns1 gene partially rescued the erg12 mutant as well as the previously 
identified erg mutants erg7 and erg25 (Figure 21 and 22), indicating that up-regulation of 
Mns1 enzyme may play a role in the perturbed mevalonate or ergosterol pathway. The 
inhibitor of 𝛼1,2-mannosidase could block the abnormal oligosaccharides formation, 
leading to reduce the metastasis and tumor growth [14,30]. Inhibitors of this enzyme may 
help in designing novel therapeutic agents that prevent misfolded proteins degradation in 
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some genetic diseases that are characterized by rapid degradation of misfolded 
glycoproteins. Kifunensine is one of the known inhibitors 𝑜𝑓 𝛼1,2-mannosidase [30]. 
Chitin synthase enzyme Chs1 (not represented in humans) is another enzyme that 
functions in cell wall oligosaccharides formation and is involved in protein glycosylation 
process. This enzyme converts UDP-N-acetylglucosamin (UDP-GlcNAc ) to chitin. The 
chitin then connects to 𝛽-1,3-glucan and 𝛽-1,6-glucan which in turn link to mannan to 
form higher polysaccharides cell wall [18,22]. The chs1 gene was found in our screening 
as a suppressor for erg mutants. The plasmids that contained chs1 gene did not rescue the 
erg12 mutant (Figure 21) but rescue erg7 and erg25 (Figure 22), indicating that Chs1 
must play a role in the ergosterol pathway. Targeting chitin synthase is a new approach 
that is under clinical trial to develop new and safe antifungal agents such as nikkomycin 
[18]. 
In addition, UDP-glucose 4-epimerase enzyme Uge1 (GALE in human) involved 
in galactosylation of glycoproteins in S. pombe in Leloir pathway (Figure 7). The enzyme 
converts β-D-galactose to glucose-1-phosphate in S. pombe [28,32]. uge1 was found in 
our screening as a multiple-copy suppressor for ergosterol mutations. The plasmids that 
contain uge1 gene rescued the erg12 mutant (Figure 21) as well as the previously 
identified erg mutants erg7 and erg25 (Figure 22), indicating the genetic connection of 
Uge1 enzyme to the ergosterol pathway. Inhibitor of glucan synthase is a new class of 






In this study, we have identified a missense mutation in erg12 encoding mevalonate 
kinase that is required for mevalonate and ergosterol biosynthesis (Figure14). Consistent 
with our previously identified mutations in erg11-1, erg7-1, and erg25-1, this mutation 
likely perturbs the ergosterol biosynthesis and thereby sensitizing the cells to HU by 
cytokinesis arrest or other mechanisms. This result is consistent with our hypothesis of an 
alternative cell-killing mechanism of HU. The mevalonate pathway has an essential role 
in cell growth regulation. It is therefore a potential target for anti-cancer chemotherapy 
[13,20]. Studies have shown that combination therapy of the two classes of MVK 
inhibitors statin and bisphosphonate can extend the lifespan of some cancer patients 
[19,29]. The suppressor genes that we have found in this study might shed new light on 
the incompletely understood cell-killing mechanisms of HU. Further characterization for 
these suppressor genes may provide new therapeutic targets or promote the development 
of new combination therapies to overcome drug resistance or improve the therapeutic 
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